Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Selexipag - Actelion/Nippon Shinyaku

Drug Profile

Selexipag - Actelion/Nippon Shinyaku

Alternative Names: ACT-293987; JNJ-678896049; NS-304; Uptravi

Latest Information Update: 30 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nippon Shinyaku
  • Developer Actelion Pharmaceuticals; Nippon Shinyaku
  • Class Acetamides; Antihypertensives; Pyrazines; Small molecules; Sulfonamides; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pulmonary arterial hypertension
  • Phase III Arteriosclerosis obliterans; Pulmonary hypertension
  • Phase II Raynaud's disease; Spinal stenosis

Most Recent Events

  • 17 May 2019 Actelion plans a phase III SELECT trial for Pulmonary hypertension in January 2019 (PO) (NCT03689244) (EudraCT2018-002823-41)
  • 08 May 2019 Actelion plans a phase II/III trial for Pulmonary arterial hypertension in August 2019 (EudraCT2018-004887-74) (NCT03942211)
  • 25 Aug 2018 Adverse events data from a phase III GRIPHON and its extension trial in Pulmonary arterial hypertension presented at the Annual Congress of the European Society of Cardiology (ESC-card 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top